Techulon wins $1.9M DARPA contract to develop superbug treatment

05/10/2013 | Genetic Engineering & Biotechnology News

Techulon landed a Phase II, $1.9 million contract with the Defense Advanced Research Projects Agency to further develop its therapeutic program for multidrug-resistant bacteria, or superbugs. The firm plans to use the money to take a nanotherapeutic agent toward clinical trials.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
MEDICAL SCIENCE LIAISON - 14000002RO
Abbott
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Medical Director - Cataract
Abbott
Santa Ana, CA